Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of COMP-14 plus rituximab as first-line treatment for aggressive B-cell non-Hodgkin lymphoma with cardiovascular risk
2008-002115-41Phase 2Active
- Sponsor
- Asociación Dr. Peset para el estudio de la Hematología
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone in non-Hodgkin lymphoma (NHL), sponsored by Asociación Dr. Peset para el estudio de la Hematología. Primary endpoint: Overall response. Started Jun 2008; status: active.
02
Drugs
doxorubicinrituximabcyclophosphamidevincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2008-002115-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002115-41.